MDNA vs. VBV, CUS, FRX, AIM, APM, IPA, ITH, CRDL, GPH, and GXE
Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Fennec Pharmaceuticals (FRX), Aimia (AIM), Andean Precious Metals (APM), ImmunoPrecise Antibodies (IPA), International Tower Hill Mines (ITH), Cardiol Therapeutics (CRDL), Graphite One (GPH), and Gear Energy (GXE). These companies are all part of the "pharmaceutical products" industry.
Medicenna Therapeutics vs.
VBI Vaccines (TSE:VBV) and Medicenna Therapeutics (TSE:MDNA) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, community ranking, analyst recommendations, profitability and dividends.
Medicenna Therapeutics has lower revenue, but higher earnings than VBI Vaccines. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.
In the previous week, VBI Vaccines' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.
VBI Vaccines has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. VBI Vaccines' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.
Medicenna Therapeutics received 37 more outperform votes than VBI Vaccines when rated by MarketBeat users. However, 70.83% of users gave VBI Vaccines an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.
13.0% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Medicenna Therapeutics beats VBI Vaccines on 6 of the 11 factors compared between the two stocks.
Get Medicenna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicenna Therapeutics Competitors List
Related Companies and Tools
This page (TSE:MDNA) was last updated on 2/22/2025 by MarketBeat.com Staff
